$GILD News More positive tests for hep C drug boost

New Post Public Reply Private Reply Replies (0) Message Board

Jan 31, 2014 at 4:05 PM

$GILD News

More positive tests for hep C drug boost AbbVie and Enanta shares 10:52 a.m. Today - blogs.marketwatch.com
Cash ain’t trash 1:55 p.m. Jan. 28, 2014 - The Trading Deck
Beware the dead-cat bounce 1:24 p.m. Jan. 28, 2014 - Michael Ashbaugh
Beware the dead-cat bounce 1:06 p.m. Jan. 28, 2014 - Michael Ashbaugh
The market puts a few feathers in its cap 1:58 p.m. Jan. 23, 2014 - The Trading Deck
Are the prevailing technicals bullish, or bearish? 11:54 a.m. Jan. 17, 2014 - Michael Ashbaugh
U.S. stocks drop on Goldman, Citi; Nasdaq edges up 4:07 p.m. Jan. 16, 2014 - Laura Mandaro
Nu Skin sinks on China probe; Best Buy hits 6-month low 4:04 p.m. Jan. 16, 2014 - Ben Eisen
S&P 500 drops from record, but Nasdaq ekes out gain: Stock market live blog recap 4:02 p.m. Jan. 16, 2014 - blogs.marketwatch.com
Speculators turn the heat up to ‘soft boil’ 3:54 p.m. Jan. 16, 2014 - The Trading Deck
Mounting optimism for hepatitis C drug boosts Gilead to lead S&P 500 3:09 p.m. Jan. 16, 2014 - blogs.marketwatch.com
Earnings boost Micron, drag on Container Store 4:24 p.m. Jan. 8, 2014 - Ben Eisen
Buying the 2014 recovery 12:01 a.m. Jan. 7, 2014 - Jim Lowell
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
3 top trades for 2014 6:00 a.m. Dec. 30, 2013 - Jeff Reeves
Investors warm up to Gilead's test results; shares climb 5% by close 4:49 p.m. Dec. 18, 2013 - blogs.marketwatch.com
Twitter hits record; Campbell, Starbucks head south 4:25 p.m. Dec. 10, 2013 - Saumya Vaishampayan
Speculators should retain a flexible approach 1:41 p.m. Dec. 4, 2013 - The Trading Deck
Nasdaq’s climb reflects vast shifts in global economy 10:18 a.m. Nov. 27, 2013 - Dan Strumpf
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com

Biotech Sector Performance January 2014 Strong, but What's Ailing Celgene? 2:12 p.m. Today - TheStreet.com
Abbvie Strong Hep C Drug Data and the Looming Battle With Gilead Sciences 10:07 a.m. Today - TheStreet.com
Gilead Sciences Inc Retains Buy Recommendation 9:00 a.m. Today - TheStreet.com
Idenix to Raise Funds, Shares up - Analyst Blog 5:20 p.m. Jan. 29, 2014 - Zacks.com
Why Caution Is Prevailing in Biotechs Into and After Earnings 11:29 a.m. Jan. 29, 2014 - 247WallSt.com
UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside 7:35 a.m. Jan. 29, 2014 - 247WallSt.com
Gilead Sciences Inc. (GILD): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Jan. 29, 2014 - Zacks.com
6 Biotechnology Stocks to Buy Now 6:00 a.m. Jan. 29, 2014 - InvestorPlace.com
Don't Underestimate Amgen: Part 2A, Cardiovascular And Oncology Pipeline Products 3:01 a.m. Jan. 29, 2014 - Seeking Alpha
Gilead Sciences Inc (GILD): Today's Featured Drugs Winner 5:00 p.m. Jan. 28, 2014 - TheStreet.com
Biotechs - especially Biogen, Celgene, Gilead - have further to rise, DB says 11:58 a.m. Jan. 28, 2014 - Seeking Alpha
Idenix Pharma CEO Speaks On Plans for the $107 Million Just Raised 10:22 a.m. Jan. 28, 2014 - TheStreet.com
Big cap biotech pushed at Deutsche 9:12 a.m. Jan. 28, 2014 - Seeking Alpha
Is The Healthcare Sector Pulling Back Or Crashing? 5:40 a.m. Jan. 28, 2014 - Seeking Alpha
Cramer's Mad Money - We Are In Reset Mode (1/27/14) 5:06 a.m. Jan. 28, 2014 - Seeking Alpha
Growth Portfolio Super Bowl: Gilead Vs. Polaris 12:09 a.m. Jan. 28, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Market Reset 8:33 p.m. Jan. 27, 2014 - TheStreet.com
CHMP Positive on Bayer's Riociguat - Analyst Blog 4:30 p.m. Jan. 27, 2014 - Zacks.com
Top 2013 Drug Approvals: Pharma Stocks 3:58 p.m. Jan. 27, 2014 - Seeking Alpha
Obamacare Boosts Health Funds 11:26 a.m. Jan. 27, 2014 - TheStreet.com

Mylan Named as Gilead's Exclusive Branded Medicines Business Partner for India 12:30 a.m. Today - PR Newswire - PRF
Gilead Sciences to Release Fourth Quarter and Year End 2013 Financial Results on Tuesday, February 4, 2014 5:00 p.m. Jan. 28, 2014 - BusinessWire - BZX
Gilead Announces Executive Promotions 5:00 p.m. Jan. 27, 2014 - BusinessWire - BZX
European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection 9:09 a.m. Jan. 17, 2014 - BusinessWire - BZX
Acceptance of NDA for Review, Acquisitions of Development Rights, Earnings Release Schedulesm and New Leaders - Research Report on Gilead, Lilly, Allergan, Incyte, and Varian Medical Systems 8:00 a.m. Jan. 16, 2014 - PR Newswire - PRF
U.S. FDA Accepts New Drug Application for Gilead’s Idelalisib for the Treatment of Refractory Indolent Non-Hodgkin’s Lymphoma 8:30 a.m. Jan. 13, 2014 - BusinessWire - BZX
Biotoscana agrees to acquire United Medical to expand commercial presence in Brazil and create a leading regional specialty pharmaceutical company in South America 1:15 a.m. Jan. 13, 2014 - BusinessWire - BZX
Gilead Sciences to Present at the 32nd Annual JPMorgan Healthcare Conference on Monday, January 13 5:00 p.m. Jan. 10, 2014 - BusinessWire - BZX
Retirement Announcements, Stock Price Movements, and Scheduled Conferences Presentations - Research Report on Gilead, Aegerion, Celldex, Alnylam, and Ironwood 8:00 a.m. Jan. 9, 2014 - PR Newswire
Stock Price Movements, Conference Presentation Schedules, and Expanded Sharing of Clinical Data - Research Report on Gilead, Express Scripts, Sanofi, Agilent, and Kythera Biopharma 8:00 a.m. Jan. 8, 2014 - PR Newswire
Galectin Therapeutics Receives Patent for Combination Treatment for Liver Fibrosis 12:17 p.m. Jan. 7, 2014 - ACCESSWIRE
Notable Buzzers: Apple Inc, Stereotaxis Inc, Tiger Oil and Energy Inc, Gilead Sciences Inc 11:00 a.m. Jan. 7, 2014 - ACCESSWIRE
Gilead Sciences' Kevin Young CBE, Executive Vice President, Commercial Operations, to Retire 4:29 p.m. Jan. 6, 2014 - BusinessWire
Critical Alerts For Trina Solar, Gilead Sciences, Priceline, Akamai, and Anglogold Ashanti Released By InvestorsObserver 9:31 a.m. Jan. 2, 2014 - PR Newswire
Technical Briefing on Health Care Sector: Gilead Sciences, Halozyme Therapeutics, NPS Pharma, and InterMune 8:00 a.m. Dec. 26, 2013 - PR Newswire
Clinical Trial Results, Stock Movements, Grants & Donations, and Drug Resubmissions - Research Report on Gilead, WellPoint, Zoetis, Teleflex, and Orexigen 8:00 a.m. Dec. 23, 2013 - PR Newswire
Obesity Stock Plays Standing Out from the Crowd 10:04 a.m. Dec. 20, 2013 - ACCESSWIRE
Gilead Sciences Tops List of California's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking 8:00 a.m. Dec. 19, 2013 - Marketwire
Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients 8:30 a.m. Dec. 18, 2013 - BusinessWire
FDA Consents, Pending Acquisition Approvals, Program Deployments, and Stock Movements - Research Report on Gilead, Elan, Agilent, Alkermes and Hospira 8:00 a.m. Dec. 18, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Quantum Space Joins $185M NASA Lunar Transport Deal

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

D-Wave's Legal Trouble: Securities Fraud Suit Looms

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

NatGold Pulling NATG From MEXC Amid Security Concerns

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

ASTS Faces Class Action; Investors Beware of Pitfalls

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Intelligent Communication Forum Eyes Global Ecosystem Shift

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Historic Records Set at 2026 CNO Monumental Marathon

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...